Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wave Life Sciences USA, Inc.
Age
25–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion
Ambulatory, male or female patients aged ≥25 - ≤65 years
Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13
You may not be if
Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years
Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 halflives of the oligonucleotide, whichever is longer
Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy
Inability to undergo brain MRI
Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
